CRT0066101 dihydrochloride|cas:1883545-60-5|西域试剂

CRT0066101 dihydrochloride,99.88%

产品编号：Bellancom-15698A| CAS NO：1883545-60-5| 分子式：C₁₈H₂₄Cl₂N₆O| 分子量：411.33

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-15698A	￥820.00	杭州北京（现货）
Bellancom-15698A	￥1500.00	杭州北京（现货）
Bellancom-15698A	￥3400.00	杭州北京（现货）
Bellancom-15698A	￥6100.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CRT0066101 dihydrochloride

产品介绍

CRT0066101 dihydrochloride是有效，选择性的 PKD 抑制剂，对PKD1，2和3的IC₅₀值分别为1，2.5和2 nM。

生物活性

CRT0066101 dihydrochloride is a potent and specific PKD inhibitor with IC₅₀ values of 1, 2.5 and 2 nM for PKD1, 2, and 3 respectively.

体外研究

CRT0066101 specifically blocks PKD1/2 activity and does not suppress PKCα/PKCβ/PKCε activity in multiple cancer cell types including A549 (lung) and MiaPaCa-2 (pancreas). CRT0066101 significantly inhibits Panc-1 cell proliferation with an IC₅₀ value of 1 µM. Treatment with CRT0066101 results in a 6-10 fold induction of apoptosis in Panc-1 cells. CRT0066101 significantly reduces cell proliferation of Colo357, Panc-1, MiaPaCa-2, and AsPC-1 cells but has a modest effect in Capan-2 cells. CRT0066101 (5 µM) blocks both the basal and NT-induced pS916-PKD1/2 (activated PKD1/2) in Panc-1 and Panc-28 cells. CRT0066101 reduces PKD-dependent NF-κB activation and NF-κB-dependent gene expressions in Panc-1.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Optimal therapeutic concentrations (8 µM) of CRT0066101 are detectable 6 h after oral administration of this drug. CRT0066101 given orally (80 mg/kg/day) for 28 days significantly abrogates PaCa growth in Panc-1 subcutaneous xenograft model. Activated PKD1/2 expression in the treated tumor-explants is significantly inhibited with peak tumor concentration (12 µM) of CRT0066101 achieved within 2 h after oral administration. Further, CRT0066101 given orally (80 mg/kg/day) for 21 days in Panc-1 orthotopic model potently blocks tumor growth in vivo. CRT0066101 significantly reduces Ki-67⁺ proliferation index, increases TUNEL+ apoptotic cells (p<0.05), and abrogates expression of NF-κB-dependent proteins including cyclin D1, survivin, and cIAP-1.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

H₂O : 50 mg/mL (121.56 mM; Need ultrasonic)

DMSO : 11.36 mg/mL (27.62 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4311 mL	12.1557 mL	24.3114 mL
5 mM	0.4862 mL	2.4311 mL	4.8623 mL
10 mM	0.2431 mL	1.2156 mL	2.4311 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： PBS
Solubility: 25 mg/mL (60.78 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 1.14 mg/mL (2.77 mM); Clear solution

此方案可获得 ≥ 1.14 mg/mL (2.77 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 11.4 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.14 mg/mL (2.77 mM); Clear solution

此方案可获得 ≥ 1.14 mg/mL (2.77 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 11.4 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.14 mg/mL (2.77 mM); Clear solution

此方案可获得 ≥ 1.14 mg/mL (2.77 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 11.4 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。